<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7910918</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5452</journal-id>
<journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Inherit. Metab. Dis.</journal-id>
<journal-title-group>
<journal-title>Journal of inherited metabolic disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0141-8955</issn>
<issn pub-type="epub">1573-2665</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29460030</article-id>
<article-id pub-id-type="pmc">6041169</article-id>
<article-id pub-id-type="doi">10.1007/s10545-018-0153-8</article-id>
<article-id pub-id-type="manuscript">NIHMS944526</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Succinic Semialdehyde Dehydrogenase Deficiency, a Disorder of GABA Metabolism: An Update on Pharmacological and Enzyme-Replacement Therapeutic Strategies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vogel</surname>
<given-names>Kara R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ainslie</surname>
<given-names>Garrett R.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walters</surname>
<given-names>Dana C.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McConnell</surname>
<given-names>Alice</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dhamne</surname>
<given-names>Sameer C.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rotenberg</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roullet</surname>
<given-names>Jean-Baptiste</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gibson</surname>
<given-names>K. Michael</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">a</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Neuroscience, University of Wisconsin, Madison, WI, USA</aff>
<aff id="A2">
<label>2</label>Theravance Biopharma Inc., USA, South San Francisco, CA, USA</aff>
<aff id="A3">
<label>3</label>Department of Pharmacotherapy, Washington State University, College of Pharmacy, Spokane, WA, USA</aff>
<aff id="A4">
<label>4</label>Speragen, Inc., Austin, TX, USA</aff>
<aff id="A5">
<label>5</label>Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA</aff>
<author-notes>
<corresp id="FN1"><label>a</label><bold>Corresponding Author:</bold> K. M. Gibson Department of Pharmacotherapy, College of Pharmacy, 412 E. Spokane Falls Blvd, Health Sciences Building Room 210, Spokane, WA 99204; phone 509 358 7954; <email>mike.gibson@wsu.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>Competing Interest Statement</bold>
</p>
<p>The authors have no competing interests associated with the content of this manuscript</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p>
<bold>Conflicts of Interest</bold>
</p>
<p>KRV, no conflict of interest; GRA, no conflict of interest; JBR, no conflict of interest; KMG, no conflict of interest; DCW, no conflict of interest; AM, no conflict of interest; AR, no conflict of interest</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2019</year>
</pub-date>
<volume>41</volume>
<issue>4</issue>
<fpage>699</fpage>
<lpage>708</lpage>
<!--elocation-id from pubmed: 10.1007/s10545-018-0153-8-->
<abstract>
<p id="P1">We update the status of research on succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD), a rare disorder of GABA metabolism. An unusual disorder featuring accumulation of both GABA and its neuromodulatory analog, gamma-hydroxybutyric acid (GHB), recent studies have advanced the potential clinical application of NCS-382, a putative GHB receptor antagonist. Animal studies have provided proof-of-concept that enzyme replacement therapy could represent a long-term therapeutic option. The characterization of neuronal stem cells (NSCs) derived from <italic>aldehyde dehydrogenase 5a1<sup>−/−</sup></italic> (<italic>aldh5a1<sup>−/−</sup></italic>) mice, the murine model of SSADHD, has highlighted NSC utility as an in vitro system in which to study therapeutics and associated toxicological properties. Gene expression analyses have revealed that transcripts encoding GABA<sub>A</sub> receptors are down-regulated and may remain largely immature in <italic>aldh5a1<sup>−/−</sup></italic> brain, characterized by excitatory as opposed to inhibitory outputs, the latter being the expected action in the mature central nervous system. This indicates that agents altering chloride channel activity may be therapeutically relevant in SSADHD. The most recent therapeutic prospects include mTOR (mechanistic target of rapamycin) inhibitors, drugs that have received attention with the elucidation of the effects of elevated GABA on autophagy. The outlook for novel therapeutic trials in SSADHD continues to improve.</p>
</abstract>
<kwd-group>
<kwd>GABA</kwd>
<kwd>succinic semialdehyde dehydrogenase deficiency</kwd>
<kwd>gamma-hydroxybutyric aciduria</kwd>
<kwd>mTOR</kwd>
<kwd>Torin 2</kwd>
<kwd>enzyme replacement therapy</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>